Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 974-987

  Szepeshazi, Karoly ^a   Schally, Andrew V ^a,b   Nagy, Attila ^a   Halmos, Gabor ^a   Groot, Kate ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cytotoxic LH RH analogs; Experimental breast cancer; LH RH receptors; Targeted cancer therapy

Indexed keywords

2 PYRROLINODOXORUBICIN; ANTINEOPLASTIC AGENT; DOXORUBICIN; DOXORUBICIN DERIVATIVE; ESTROGEN; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 0031441622     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00009     Document Type: Article

References (46)

1. Carbone PP, Nixon DW, Fennelly J, et al. Adjuvant systemic therapy. Cancer 1990; 65: 2108-9.
2. Tormey DC, Gray R, Gilchrist K, et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer 1990; 65: 200-6.
3. Bonadonna G. From adjuvant to neoadjuvant chemotherapy in high-risk breast cancer the experience of the Milan Cancer Institute. Steiner Award Lecture 1992. Int J Cancer 1993; 55: 1-4.
4. Magrath T. Targeted approaches to cancer therapy. Int J Cancer 1994; 56: 163-6.
5. Schally AV, Nagy A, Szepeshazi K, et al. LHRH analogs with cytotoxic radicals. In: Filcori M, Flamigni G, eds. Treatment with GNRH analogs: controversies and perspectives. London: Parthenon 1996: 33-44.
6. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E, III, Bast RC, Jr. Kufe DE, Morton DL, Weichselbaum RR, eds. Cancer medicine, 4th edn. Baltimore, MD: Williams and Wilkins 1997: 1067-86.
7. Eidne KA, Flanagan CA, Harris NS, Millar RP. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab, 1987; 64: 425-32.
8. Yano T, Korkut E, Pinski J, et al. Inhibition of growth of MCF-7 Mill human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat 1992; 21: 35-45.
9. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989; 3: 137-47.
10. Baumann HH, Kiesel L, Kaufman M, Bastert G, Runnebaum B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 1993; 25: 37-46.
11. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotropin releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. Br J Cancer 1990; 62: 96-9.
12. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992; 75: 207-12.
13. Motta M, Dondi D, Limonta P, et al. Extrapituitary sites of action of LHRH agonists. In Flilicori M, Flamigni C, eds. Treatment with GnRH analogs: controversies and perspectives. London: Parthenon 1996: 25-31.
14. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Hum Reprod 1994; 9: 1364-79.
15. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 1994; 55: 144-8.
16. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin or a combination. Breast Cancer Res Treat 1992; 21: 181-92.
17. Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anti-Cancer Drugs 1992, 3: 109-16.
18. Szepeshazi K, Schally AV, Halmos G, Szoke B, Groot K, Nagy A. Effect of cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Res Treat 1996; 40: 129-39.
19. Nagy A, Armatis P, Schally AV. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA 1996; 93: 2464-9.
20. Nagy A, Schally AV, Armatis P, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996; 93: 7269-73.
21. Weiss RB. The Anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19: 670-86.
22. Israel M, Modest EJ, Frie E. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 1975; 35: 1365-8.
23. Janaky T, Juhasz A, Bajusz S, et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci USA 1992; 89: 972-6.
24. Aschoff A, Jantz M, Jirikowski GF. In-situ end labelling with bromodeoxyuridine - an advanced technique for the visualization of apoptotic cells in histological specimens. Horm Metab Res 1996; 28: 311-4.
25. Kyprianou N, Isaacs J. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988; 122: 552-62.
26. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci USA 1996; 93: 2938-42.
27. Begent RHJ. UICC/CRC Conference on targeted cancer therapy. Int J Cancer 1993; 55: 355-8.
28. Siegall C. Targeted toxins as anticancer agents. Cancer 1994; 74: 1000-12.
29. Sivam GP, Martin PJ, Reisfeld RA, Mueller BM. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res 1995; 55: 2352-6.
30. Ripamonti M, Pezzoni G, Pesenti E, et al. In vivo antitumour activity of FCE 23762, a methoxymorpholinyl derivitive of doxorubicin active on doxonibicin-resistant tumour cells. Br J Cancer 1992; 65: 703-7.
31. Inaba M, Kobayashi T, Tashiro T, et al. Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer 1989; 64: 1577-82.
32. Svensson HP, Vrudhula VM, Emswiler JE, et al. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Cancer Res 1995; 55: 2357-65.
33. Jungwirth A, Schally A, Nagy A, et al. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 1997, 10: 877-84.
34. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
35. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993; 52: 1945-51.
36. Wijsman JH, Jonker RR, Keijzer R, et al. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem 1993; 41: 7-12.
37. Li X, Darzynkiewicz Z. Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif 1995; 28: 571-9.
38. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metast Rev 1992; 11: 121-39.
39. s sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2507-10.
40. Huschtscha LI, Bartier WA, Andersson Ross CE. Tattersall MHN. Characteristics of cancer cell death after exposure to cytotoxic dnigs in vitro. Br J Cancer 1996; 73: 54-60.
41. Malcomson RDG, Oren M, Wyllie AH, Harrison DJ. p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer 1995; 72: 952-57.
42. Wood AC, Elvin P, Hickman JA. Induction of apoptosis by anti-cancer drugs with disparate modes of action: kinetics of cell death and changes in c-myc expression. Br Cancer 1995; 71: 937-41.
43. Huddart RA, Titley J, Robertson D, Williams GT, Horwich A, Cooper CS. Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines. Eur J Cancer 1995; 31A: 739-46.
44. Ling YH, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multi drug-resistant cells. Cancer Res 1993; 53: 1845-52.
45. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996; 32A: 921-6.
46. Lau DHM, Duran GE, Lewis AD, Sikic BI. Metabolic conversion of methoxymorpholinyl doxonibicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer 1994; 70: 79-84.